Background Mutation testing in the context of neoadjuvant therapy must be performed on biopsy samples. Given the issue of tumour heterogeneity, this raises the question of whether the biopsies are representative of the whole tumour. Here we have compared the mutation profiles of colorectal biopsies with their matched resection specimens. Methods We performed next-generation sequencing (NGS) analysis on 25 paired formalin-fixed, paraffin-embedded colorectal cancer biopsy and primary resection samples. DNA was extracted and analysed using the TruSight tumour kit, allowing the interrogation of 26 cancer driver genes. Samples were run on an Illumina MiSeq. Mutations were validated using quick-multiplex-consensus (QMC)-polymerase chain reaction (PCR) in conjunction with high resolution melting (HRM). The paired biopsy and resection tumour samples were assessed for presence or absence of mutations, mutant allele frequency ratios, and allelic imbalance status. Results A total of 81 mutations were detected, in ten of the 26 genes in the TruSight kit. Two of the 25 paired cases were wild-type across all genes. The mutational profiles, allelic imbalance status, and mutant allele frequency ratios of the paired biopsy and resection samples were highly concordant (88.75-98.85%), with all but three (3.7%) of the mutations identified in the resection specimens also being present in the biopsy specimens. All 81 mutations were confirmed by QMC-PCR and HRM analysis, although four low-level mutations required a co-amplification at lower denaturation temperature (COLD)-PCR protocol to enrich for the mutant alleles. Conclusions Diagnostic biopsies are adequate and reliable materials for molecular testing by NGS. The use of biopsies for molecular screening will enhance targeted neoadjuvant therapy.
Introduction
Colorectal cancer (CRC) is the third most common malignancy and a fifth leading cause of cancer deaths worldwide [1] . In the UK, CRC is the fourth most common cancer and the fifth most common cause of cancer deaths, accounting for 10% of all cancer deaths [2] . Recent advances in genome sequencing technologies have enabled greater understanding of the molecular mechanisms of tumourigenesis and aided the identification of clinically relevant biomarkers for diagnosis and personalised therapeutics [3, 4] . Predictive biomarkers are currently used to guide the selection of targeted therapies for personalised medicine. One example of a 'stratified medicine' approach in CRC is tumour assessment for the presence of mutations in the KRAS or NRAS genes, which predicts a lack of response to epidermal growth factor receptor (EGFR)-targeted antibodies such as panitumumab or cetuximab [4, 5] . Constitutive activation of either KRAS or NRAS results in excess signalling through the RAS/ mitogen-activated protein kinase pathway which cannot be negated by the anti-EGFR monoclonal antibody therapies.
Currently, tumour materials from both biopsy (Bx) and resection specimens (Rx) are recommended for use in the predictive testing of adjuvant targeted therapy response in stage II-III CRC, in the absence of metastatic or recurrent tumour [6] . However, the use of neoadjuvant therapy in patients with CRC is likely to increase, and at present, many predictive biomarkers for neoadjuvant therapy prediction are under study [7, 8] . Whilst neoadjuvant therapy is available for patients with rectal tumours, a clinical trial of neoadjuvant chemotherapy for locally advanced colonic cancer was recently started in the UK and elsewhere [7] [8] [9] [10] . In the setting of neoadjuvant therapy, Bx specimens may be the only available specimens to test KRAS, NRAS and BRAF mutations as recommended for the current standard of care of metastatic CRCs. If the studies on the use of neoadjuvant therapy show desirable outcomes, then the diagnostic Bx specimens may become the only material available for predictive testing in the neoadjuvant settings [11] . CRC develops as a consequence of waves of clonal expansion, resulting from mutations called 'driver mutations' giving a selective advantage [12] . These driver mutations, which are responsible for early clonal sweeps through the adenoma-carcinoma sequence, should therefore be predominantly present in most of the tumour cells and consequently should be present in any Bx samples of an individual tumour.
To confirm whether this is indeed the case and whether diagnostic Bx specimens are appropriate for predictive testing, we have carried out mutation screening of 25 paired diagnostic Bx and their matched Rx. A sensitive next-generation sequencing (NGS) approach was used to assess the presence of mutations in a panel of 26 genes involved with solid tumours.
Materials and Methods

Clinical Samples
Formalin-fixed, paraffin-embedded (FFPE) sporadic CRC tumour blocks were retrieved from the archives of the Nottingham University Hospitals Department of Histopathology. All patients had undergone surgery between 2004 and 2005. Cases were selected based on the availability of clinicopathological data and the presence of at least 50% tumour cells in both Bx and Rx. DNA was extracted using the Qiagen mini kit from 25 cases of paired Bx and Rx samples as previously described [11] . Baseline characteristics are reported in Online Resource Table 1 (see the electronic supplementary material).
NGS Library Preparation
Mutation profiles were determined using the TruSight tumour kit (Illumina, USA) and samples run on an Illumina MiSeq (Illumina, USA). The TruSight tumour kit offers deep coverage of 26 genes across 175 amplicons (a minimum 1000 × coverage, an average of 7000 × coverage). Each sample underwent a quality control (QC) step to test for template integrity according to the kit manufacturer's instructions. A polymerase chain reaction (PCR)-based library preparation was carried out in accordance with the manufacturers' instructions. The libraries were cleaned up then diluted to a final concentration of 4 nM before pooling. Captured libraries were amplified and sequenced as paired-end reads on a MiSeq flow cell, with a total of 12 samples being run on each cell.
NGS Data Analysis
Base calling, quality score assignment and trimming of low-quality reads (using a minimum Q score of 20) were performed on the MiSeq reporter v2.1 suite. The generated FASTQ files were aligned to the reference genome (hg19). Following alignment, the sequence variants [single-nucleotide variants (SNVs) and insertions or deletions (indels)] detected in the generated BAM files were assembled into a vcf format. The VariantStudio™ v2.1 analyser was used to perform variant filtering and annotation. The following criteria were used to define sequence variants-germline and somatic-and rule out mutation artefacts: (1) average wild-type read depth of > 500 × per pool (see Online Resource Table 2 in the electronic supplementary material), (2) occurrence in both forward and reverse sequencing pools, and (3) > 3% mutant allele frequency (MAF) in the merged vcf files. The Single Nucleotide Polymorphism Database (dbSNP) reference was used to separate germline from somatic sequence variants.
To assess the intra-assay variability of the NGS platform, we performed short-term precision assay by testing one sample in eight replicates in the same run. The inter-assay variability was assessed with the long-term precision assay by testing the same sample in three different runs. For each precision assay, we determined the coefficient of variation (CV).
QMC-PCR and HRM Analysis
As a means of validating the mutations detected by NGS, the samples were also analysed using the quick-multiplexconsensus (QMC)-PCR in conjunction with a high resolution melting (HRM) protocol as previously described [13] . Derivative and difference plots were generated to separate mutant from wild-type samples, as described elsewhere [13, 14] .
Molecular Similarity Between Bx and Rx
To verify if the Bx were representative of the Rx at the molecular level, we investigated the similarities between the diagnostic Bx and Rx pairs by using three indices which have shown relevance in the clinical and biological behaviours of cancers: somatic mutation profiles, MAF ratios, and allelic imbalance (AI) status-within the limitations of the TruSight tumour targeted panel. Since each of the pairs of Bx and Rx are from the same tumours, they must be similar at the molecular level, i.e. not only must their mutation profiles match, but their mutant frequency ratios and AI scores must be in the same ranges.
A crude percentage concordance was used to calculate the extent to which the diagnostic Bx match the somatic mutation profiles, MAF ratios, and AI status of their corresponding Rx, whilst the kappa test [QuickCalcs (http:// www.graph pad.com/quick calcs /kappa 2/) and Kappa (http:// www.vassa rstat s.net/kappa .html)] was used to validate the crude percentage concordance test results [15, 16] . Mean difference in MAF between Rx and Bx was calculated using the online GraphPad software (http://www.graph pad.com).
Performance Evaluation of NGS-Based Somatic Mutation Profiling of Bx
As the 26-gene TruSight Tumour Somatic Mutation panel has translated into clinical use (http://www.clini calla bs.com. au/docto r/speci alist s-servi ces/haema tolog y-oncol ogy/), we tested the following performance indices of the NGS-based somatic mutation profiling of Bx: sensitivity, specificity, and negative and positive predictive values (NPV and PPV). See Online Resource Table 3 in the electronic supplementary material. The performance indices as used here are merely to show the similarities between Rx and Bx at the molecular level and not strictly as diagnostic tests of accuracy.
Results
The NGS short-term precision assay showed a mean CV of 12.3% (range 8.6-15.3%) for sequencing depth and 2.5% (range 1.6-4.4%) for MAF. The long-term precision assay showed a mean CV of 10.6% (range 3.2-15.1%) for sequencing depth and 2.2% (range 0.01-6.1%) for MAF. The mean sequencing depth obtained was 14,803 (range 1366-44,577), whilst the limit of detection of the mutant alleles was 3%.
Paired Bx and Rx Mutation Profiles
A total of 78 and 81 somatic mutations were found in the Bx and Rx samples, respectively. Only two out of 25 tumour pairs (8%) displayed a wild-type genotype across all 26 genes included in the panel. The distribution of mutations detected in the 25 paired samples is shown in Table 1 and Online  Resource Table 2 . In sample 9, the GNAS c.2531G>A mutation was not detected in the Bx sample. In sample 13, only the Rx contained the GNAS c.2543C>T mutation. In sample 20, both the Bx and Rx contained the TP53 c.524G>A mutation, but only the Rx contained the TP53 c.23C>T mutation. Only eight out of 25 tumours (32%) contained the full complement of the APC/KRAS(BRAF)/TP53 mutations of the Fearon and Vogelstein pathway. Furthermore, the frequency of APC mutations (56%) was lower than that of TP53 mutations (68%), and this is consistent with published data. Although overall, the MAF was 1.003-fold lower in Rx than in Bx, on a mutation-by-mutation basis, the MAF showed no consistent pattern of abundance between the Rx and Bx samples. Moreover, there was no significant difference in the mean MAF between Rx and Bx samples (difference in mean MAF = 0.753, P = 0.748). Furthermore, the three mutations not detected in Bx were present in the matched Rx at frequencies of < 4%. There were no mutations in the Bx that were not seen in the Rx (Table 1) . In all, only ten of the 26 genes in the TruSight panel were found to be mutated in the Rx and Bx samples.
Validation of Mutations
QMC-PCR in conjunction with HRM was used to validate the mutations identified, and initially 77 out of the 81 mutations (95.1%) were successfully validated (Online Resource Figure 1 , see the electronic supplementary material). The remaining four mutations (4.9%) were only validated by HRM following minor allele enrichment by the modified co-amplification at lower denaturation temperature (COLD)-PCR protocol (Online Resource Figure 2 ). These four 'false negative' samples were subsequently reassigned as 'true positives'.
Allelic Imbalance
Quantification of heterozygous single-nucleotide polymorphisms (SNPs) was used to indicate allelic loss if there was 
Concordance in Molecular Alteration Status Between Rx and Bx Pairs
To determine the similarity between Bx and their corresponding Rx at the molecular level, we determined the concordance in their somatic mutation profiles. A simple 'mutation-present-or-absent' count was used to determine the mutation status match between Bx and Rx. Only the ten mutated genes were used in this analysis, which included all 50 cases (25 Bx and 25 Rx). A total of 261 Rx-Bx mutation pairs were counted (Online Resource Figure 3 ). Of these, Bx and Rx showed concordance in 258 pairs (78 mutations and 180 no-mutations) and discordance in three pairs (all Rx: mutations/Bx: no-mutations). There was no Rx: no-mutation/ Bx: mutation pair. Also, all the mutations that matched were of the same bases in the same gene loci in Rx and Bx ( [17] ) or 'very good' agreement (see Fig. 1a) . Furthermore, the level of agreement between Bx and Rx in AI status was investigated. All 25 sample pairs with 80 informative SNP loci, cumulatively, were included in the analysis. AI status was categorised into three classes: AI with loss of wild-type allele (LWA, SNP % > 56.5%), AI with loss of polymorphic allele (LPA, SNP % < 43.3%) and nil AI (NAI, SNP % within normal range of 43.3% and 56.5%). The Rx/Bx pairs were scored concordant when their SNP classes matched, otherwise they were considered discordant. A total of 80 pairs were counted, comprising 51 out of 80 NAI pairs, seven out of 80 LWA pairs and 13 out of 80 LPA pairs. Discordance was found between Rx and Bx in ten out of 80 events (Rx/Bx: NAI/LPA = 3; NAI/ LWA = 2; LPA/NAI = 2; LWA/NAI = 2; LPA/LWA = 0 and LWA/LPA = 0) (see Table 2 ). A crude percentage concordance of 88.75% (71/80) was calculated, giving a very good agreement between Bx and Rx for AI status (Fig. 1b) . Kappa test also showed a 0.76 concordance (SE of 0.076 and 95% CI between 0.612 and 0.908). Moreover, the total MAF ratios were compared between Rx and Bx. We reasoned that if Bx were truly representative of Rx, there should be some retention of the relative MAF ratios across the tumour body, despite the presence of clonal heterogeneity. A total of 20 out of 25 sample pairs, including only Rx/Bx pairs with two or more mutations in at least one of the Rx/Bx pairs, were included in this analysis. The MAF ratios for both Rx and Bx were calculated relative to the MAF of the first gene loci MAF in each Rx sample in Table 1 . The Rx/Bx pair was considered concordant if both MAF ratios were either < 1 or > 1. If the MAF Fig. 1 Scatter plots showing the extent of agreement between Rx and Bx in the somatic mutation profile (a), AI status (b) and MAF ratios (c). All the detected mutations, regardless of the MAF, were included in the data that produced the somatic mutation profile and MAF ratio plots. The scatter plots show 'almost perfect' concordance in the somatic mutation profile to 'very good' and 'good' agreements in the AI status and MAF ratios, respectively. AI allelic imbalance, Bx biopsy, MAF mutant allele frequency, Rx resection specimen, SNP single-nucleotide polymorphism ratios for the Bx/Rx pair were < 1 and > 1, but were within 1 ± 0.05, they were also considered concordant. Otherwise, they were taken as discordant. Also, samples in which one member of the pair was missing a corresponding mutation were considered discordant and were classed as being in the Bx < 1/Rx > 1 category as the Rx MAF ratios in all those cases were > 1. A total of 58 mutation pairs were counted, comprising 52 concordant observations between Rx and Bx (comprising 45 MAF ratio pairs < 1, six MAF ratio pairs > 1 and one MAF ratio pair = 1 ± 0.05) and six discordant observations (all Bx < 1/Rx > 1). There were zero Bx > 1/Rx < 1 MAF ratio pairs. A crude percentage concordance rate of 89.6% was calculated for the total MAF ratios of Rx and Bx.
Kappa was 0.651 (SE = 0.128, 95% CI 0.400-0.901). Both tests again returned 'good' to 'very good' agreement scores between the MAF ratios of Bx and Rx samples (Fig. 1c) .
Performance Evaluation of NGS-Based Somatic Mutation Profiling of Bx
We evaluated the use of Bx for mutation detection by NGS using established tests of performance (Online Resource  Table 3 ). Using the Rx as the 'gold standard' samples and taking each of the somatic mutations detected (or not detected) as individual observations, the following parameters were derived for Bx samples: number of true positive 
Discussion
Recent advances towards personalised medicine are driven by the identification of targetable mutations. For example, treatment of non-small cell lung cancer patients with gefitinib is dependent upon EGFR mutation status [18] . Herceptin administration is only considered in a subset of breast and gastric cancer patients with HER2 amplification [18, 19] . In CRC patients with advanced disease, mutation screening of KRAS and NRAS is required prospectively if anti-EGFR monoclonal antibody therapies are being considered, as responses have only been seen in wild-type tumours [5, 20] .
Where targeted neoadjuvant chemotherapy is being offered to patients, mutation screening must be carried out on the diagnostic Bx specimen. Thus, the question arises as to whether a Bx specimen, which represents a tiny proportion of the tumour, is adequately representative of the whole tumour and thus can be used in patient stratification. Previously, we and others showed that FFPE diagnostic Bx tissues were adequate for testing microsatellite instability and other molecular alterations in CRC by low throughput methods such as HRM analysis, direct sequencing, pyrosequencing, and Therascreen Amplification Refractory Mutation System (ARMS)-Scorpion [11, 21] . Furthermore, other groups have demonstrated the feasibility and reliability of the use of small diagnostic Bx for molecular testing by NGS [22] [23] [24] [25] . In this study, despite the use of low-quality DNA template derived from FFPE tissue, we obtained a mean sequencing depth of 14,803 (range 1366-44,577) and the limit of detection for the mutant alleles was 3%. There was good short-term and long-term precision, and all 81 somatic mutations detected using the TruSight panel were also validated by QMC-PCR and HRM. Validation of low-level mutations required COLD-PCR to further enrich the mutant allele population.
In our sample set, the frequency of detected gene mutations was within the range of previously published literature [26, 27] . The most frequent mutations were in TP53, whilst APC mutation was found in 56% of tumours. The sensitivity of targeted NGS analysis allowed the detection, in the Bx samples, of all but three of the 81 mutations detected in the paired Rx. There was no significant difference in the mean MAF between Rx and Bx samples.
More importantly, we compared the degree of similarity between the Rx and Bx pairs at the molecular level using well established statistical tests and markers which have been shown to have biological and clinical importance [5, 17, [28] [29] [30] [31] [32] [33] . The presence-or-absence-of-mutation-type and the AI status tests showed very good concordance between the Rx and the Bx samples, an indication that the latter were adequately representative of the former. Furthermore, we applied the MAF ratios to test the degree of similarity between the two Bx types and found a 'good' to 'very good' concordance between them. Whilst somatic mutation profiles and AI status have established biological, prognostic and predictive utilities, MAF is currently under active clinical research for use as a marker for the estimation of tumour heterogeneity and prediction of cancer survival, targeted therapy response and the risks and foci of tumour metastases [29] [30] [31] [32] [33] .
Furthermore, the Bx samples showed relatively high indices of performance as potential clinical test materials for somatic mutation detection by NGS, an indication that Bx is an adequate material for molecular testing for neoadjuvant therapy.
Although our data indicate that Bx specimens represent a feasible material for molecular testing, to increase the probability of sampling of the dominant clone, some factors should be considered when interpreting data from tumour Bx specimens. For example, from where was the tissue taken? The centre or invasive edge of the tumour? A study performed by Baldus et al. [34] demonstrated a discrepancy in the frequency of mutations in KRAS, BRAF and PIK3CA by 8%, 1% and 5%, respectively, between the centre and the invasive edge of colorectal tumours [34] , with one explanation of this discrepancy being that the invasive edges are probably more prone to stromal contamination than the central portions of the tumour. Another factor is related to tumour clonal heterogeneity [35] . Although we did find overall a strong agreement between Rx and Bx at the molecular level, we observed that a proportion of the Rx and Bx showed MAF discrepancies at some loci and that three out of 81 Bx samples did not show the corresponding mutations which were observed in the Rx samples with MAFs < 4%. On the basis of these factors, we advocate that diagnostic Bx with intent for molecular testing should sample multiple tumour areas to enhance mutation detection.
This study is limited by the number of SNPs that could be interrogated to allow a more comprehensive AI status analysis-the TruSight panel targets gene exons which have lower SNP densities compared to introns. Another limitation of this study is the small sample size used for the evaluation of Bx as a suitable candidate for molecular testing by NGS. The use of a larger sample size is perhaps necessary to validate the use of diagnostic Bx as an adequate Bx for mutation detection on the NGS platform.
In conclusion, we have shown a high concordance between matched Bx and Rx within the mutation distributions of the genes in the TruSight tumour panel, suggesting that the use of diagnostic Bx is not only feasible, but also representative of the entire tumour, and thus can be used for predictive mutation screening.
